Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

Differences in the distribution of certain proteins and markers in the brain may explain why some people first experience vision changes instead of memory loss in Alzheimer's disease, finds a new ...

The association is taking legal action against the decision to move the speedway from its home of almost 100 years.

Last month, as part of a WITN First Alert Investigation, we learned of multiple hazing allegations against Phi Kappa Tau.

The FDA has approved an application to initiate a pilot study with Alpha DaRT for patients with recurrent glioblastoma, a ...

ECU officials have released a statement on hazing allegations involving the Phi Kappa Tau fraternity. ECU gives statement regarding hazing allegations at ...

BIIB080 is an antisense oligonucleotide therapy designed to target microtubule-associated protein tau mRNA and reduce the production of tau.

Biogen (NASDAQ:BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense ...

Biogen on Wednesday said BIIB080 is the first tau-targeting antisense oligonucleotide therapy to enter clinical development for Alzheimer's disease and that it is currently being evaluated in a global ...

We are encouraged by the FDA’s Fast Track designation for BIIB080, which highlights the urgent need for innovative treatments targeting tau pathology in Alzheimer’s disease,” said Priya Singhal, M.D., ...

Worley was part of a team that showed how the loss of one of the two proteins used in the test disrupts synapses and leads to ...

The results suggested that plasma MTBR-tau243 could help estimate the tauopathy load in Alzheimer's disease, improving ...